Hemoglobin C-beta-thalassemia syndrome

Hemoglobin C-beta-thalassemia syndrome (also known as HbC/beta-thalassemia) is a compound heterozygous hemoglobinopathy that results from the co-inheritance of one hemoglobin C (HbC) gene and one beta-thalassemia gene. Hemoglobin C is caused by a specific point mutation in the beta-globin gene (substitution of lysine for glutamic acid at position 6), while beta-thalassemia involves mutations that reduce or abolish production of the beta-globin chain. The combination of these two abnormal alleles leads to a chronic hemolytic anemia of variable severity, depending on whether the beta-thalassemia allele is beta-zero (no beta-globin production) or beta-plus (reduced production). The disease primarily affects the hematologic system. Key clinical features include mild to moderate hemolytic anemia, splenomegaly (enlargement of the spleen), and the presence of target cells and hemoglobin C crystals on peripheral blood smear. Patients with HbC/beta-zero-thalassemia tend to have a more severe clinical course compared to those with HbC/beta-plus-thalassemia, who may be nearly asymptomatic. Symptoms can include fatigue, pallor, jaundice, and abdominal discomfort due to splenic enlargement. Some patients may develop gallstones due to chronic hemolysis. Overall, the clinical severity of HbC/beta-thalassemia is generally milder than sickle cell disease or beta-thalassemia major. Treatment is largely supportive and guided by clinical severity. Many patients require no specific therapy beyond monitoring. Folic acid supplementation is commonly recommended to support red blood cell production. Occasional blood transfusions may be needed during aplastic crises, severe anemia, or pregnancy. Splenectomy may be considered in cases of significant splenomegaly or worsening anemia. Genetic counseling is recommended for affected individuals and carriers, particularly in populations of African, Mediterranean, or Southeast Asian descent where both hemoglobin C and beta-thalassemia mutations are more prevalent.

Common questions about Hemoglobin C-beta-thalassemia syndrome